Lineage Cell Therapeutics released results from its ongoing Phase 1/2a clinical study of its newest product, OpRegen®.
This new therapy is made up of allogeneic retinal pigment epithelium (RPE) cells that are injected into the subretinal space of the eye. Researchers are studying its efficacy in treating dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Currently, there are no FDA-approved treatments available to treat dry AMD. Untreated macular degeneration can lead to the wet form of AMD and can lead to rapid vision loss.
Initial study results showed marked improvement in macular degeneration in study subjects along with the only known cases of restoration of retinal tissue. The restored retinal tissue has been maintained for 35 months.
Twenty-four patients are enrolled in the study and they received one injection of the RPE cells, which were grown from an established cell line. 83% of the patients reported stable or improved Best Corrected Visual Acuity (BCVA). None of the study participants reported any acute or delayed inflammation or rejection events.
While no therapies are available to treat dry macular degeneration, supplements based on the AREDS 2 study can be beneficial for patients diagnosed with macular degeneration. VisiVite has several AREDS 2 supplement options.
